HER2 fragmentation and breast cancer stratification
- PMID: 20682714
- DOI: 10.1158/1078-0432.CCR-10-1501
HER2 fragmentation and breast cancer stratification
Abstract
HER2 is a tyrosine kinase receptor whose overexpression in breast cancers correlates with poor prognosis. A subset of HER2-positive tumors also expresses a series of HER2 fragments, collectively known as p95HER2. These fragments are emerging as a valuable biomarker for this subset of patients, who have a particularly poor prognosis.
Comment in
-
Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients.Clin Cancer Res. 2010 Aug 15;16(16):4226-35. doi: 10.1158/1078-0432.CCR-10-0410. Epub 2010 Jul 27. Clin Cancer Res. 2010. PMID: 20664024
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical